Overview
Parasitic disease caused by Schistosoma blood flukes, acquired through freshwater exposure. Affects over 250 million people worldwide, predominantly in Sub-Saharan Africa.
Symptoms
Symptoms | Frequency | Severity | Onset |
|---|---|---|---|
| Itching | 65% | Mild | Early |
| Rash | 55% | Mild | Early |
| Fever | 60% | Moderate | Peak |
| Cough | 40% | Mild | Peak |
| Malaise | 50% | Mild | Peak |
| Myalgia | 40% | Mild | Peak |
| Urticaria | 35% | Mild | Peak |
| Arthralgia | 20% | Mild | Peak |
| Chills | 30% | Mild | Peak |
| Headache | 35% | Mild | Peak |
| Hematuria | 50% | Moderate | Late |
| Abdominal pain | 50% | Mild | Late |
| Dysuria | 40% | Mild | Late |
| Hepatomegaly | 35% | Moderate | Late |
| Bloody stool | 20% | Moderate | Late |
| Diarrhea | 35% | Mild | Late |
| Splenomegaly | 20% | Moderate | Late |
| Weight loss | 25% | Mild | Late |
| Fatigue | 55% | Mild | Any phase |
| Loss of appetite | 30% | Mild | Any phase |
Transmission
Overview
Schistosomiasis (also known as bilharzia) is a chronic parasitic disease caused by trematode blood flukes of the genus Schistosoma. It is the second most socioeconomically impactful parasitic disease after malaria, affecting an estimated 240 million people in 78 countries, with approximately 11,700–200,000 deaths per year (GBD 2019 estimates ~11,700; older WHO estimates ~200,000) and over 700 million people at risk.
Three species cause the vast majority of human disease:
-
Schistosoma mansoni — intestinal/hepatic schistosomiasis (Africa, Middle East, South America)
-
Schistosoma haematobium — urogenital schistosomiasis (Africa, Middle East)
-
Schistosoma japonicum — intestinal/hepatic schistosomiasis (East Asia, Philippines)
The life cycle requires freshwater snails as intermediate hosts. Infected snails release free-swimming cercariae that penetrate human skin within minutes during contact with contaminated freshwater. Adult worms reside in mesenteric or vesical venous plexuses and can survive for 3-10 years (some reports up to 30 years).
Disease is primarily caused by the host immune response to schistosome eggs trapped in tissues, which provoke granulomatous inflammation and progressive fibrosis. Acute infection may cause cercarial dermatitis ("swimmer's itch") and Katayama fever. Chronic infection leads to hepatosplenic disease (S. mansoni, S. japonicum) or urogenital disease with increased risk of bladder cancer (S. haematobium — classified as a Group 1 carcinogen by IARC).
Praziquantel is the mainstay of treatment — a single oral dose achieves cure rates of 70-100%. Mass drug administration programs targeting school-age children are the primary control strategy.
Overview
Clinical Overview
Schistosomiasis is a neglected tropical disease of enormous public health importance, affecting predominantly impoverished communities in tropical and subtropical regions.
Key Clinical Facts:
-
Causative agents: S. mansoni, S. haematobium, S. japonicum (main species); S. mekongi, S. intercalatum, S. guineensis (regional importance)
-
Transmission: Skin penetration by cercariae in contaminated freshwater (rivers, lakes, irrigation canals, dams)
-
Intermediate host: Freshwater snails (Biomphalaria spp. for S. mansoni, Bulinus spp. for S. haematobium, Oncomelania spp. for S. japonicum)
-
Incubation: Cercarial dermatitis within hours; Katayama fever 2-8 weeks post-exposure; chronic disease over months to years
-
Global burden: ~240 million infected, ~700 million at risk, ~11,700-200,000 deaths/year (range reflects GBD 2019 vs older WHO estimates)
-
Treatment: Praziquantel 40-60 mg/kg (single dose), cure rate 70-100%
-
No licensed vaccine — several candidates in clinical trials
Disease Forms:
- Acute schistosomiasis: Cercarial dermatitis (swimmer's itch), Katayama syndrome
- Chronic intestinal/hepatic: S. mansoni and S. japonicum — granulomatous hepatic fibrosis, portal hypertension, hepatosplenomegaly
- Chronic urogenital: S. haematobium — hematuria, hydronephrosis, bladder fibrosis, squamous cell carcinoma of the bladder
- Ectopic schistosomiasis: CNS involvement (cerebral or spinal cord granulomas)
Special Significance:
-
WHO classifies S. haematobium infection as a Group 1 carcinogen (definite cause of bladder cancer)
-
Female genital schistosomiasis (FGS) affects an estimated 56 million women and girls, increasing HIV acquisition risk 3-4 fold
-
Schistosomiasis is a significant cause of anemia, malnutrition, and impaired cognitive development in children in endemic areas
Emergency Signs
Emergency Warning Signs
While schistosomiasis is typically a chronic disease, certain acute complications and advanced disease manifestations require urgent medical attention.
Acute Emergencies:
-
Massive hematemesis (vomiting large volumes of blood): Indicates esophageal variceal bleeding due to portal hypertension from hepatosplenic schistosomiasis. This is a life-threatening emergency requiring immediate intervention (endoscopic banding/sclerotherapy, blood transfusion, vasoactive drugs).
-
Acute abdomen: Severe abdominal pain, rigidity, and distension may indicate variceal rupture, bowel obstruction from massive polyposis, or intestinal perforation (rare).
-
Severe Katayama syndrome: High fever, respiratory distress (cough, wheeze, dyspnea), and severe systemic illness in a recently exposed traveler. Can be life-threatening if unrecognized.
-
Acute transverse myelitis: Sudden onset of lower limb weakness, sensory level, and urinary retention due to spinal cord egg granulomas (most common with S. mansoni). Constitutes a neurological emergency requiring immediate corticosteroids and praziquantel to prevent permanent paraplegia.
Neurological Warning Signs:
-
Sudden onset paraplegia or paraparesis (spinal cord involvement)
-
Seizures, altered consciousness, severe headache (cerebral involvement — more common with S. japonicum)
-
Focal neurological deficits
-
Cauda equina syndrome (lower limb weakness, saddle anesthesia, urinary/fecal incontinence)
Urological Warning Signs:
-
Gross hematuria with clots causing urinary retention
-
Flank pain with fever (indicates obstructive uropathy with secondary pyelonephritis)
-
Anuria (complete ureteral obstruction — bilateral or in a solitary kidney)
Chronic Disease Decompensation:
-
Progressive abdominal distension with ascites (portal hypertension)
-
Pedal edema, jaundice, spider nevi (hepatic decompensation — note: pure Symmers fibrosis usually preserves hepatocellular function; concurrent viral hepatitis B/C worsens prognosis)
-
Rectal prolapse (massive intestinal polyposis, particularly in children with S. mansoni)
In Travelers: Katayama syndrome may be misdiagnosed as many other febrile illnesses. Any traveler with eosinophilia, fever, and freshwater exposure in an endemic area should be evaluated for acute schistosomiasis.
Detailed Symptoms
Most common signs and symptoms
Symptom Presentation
Schistosomiasis symptoms vary by disease stage and the infecting species. Many chronically infected individuals in endemic areas are asymptomatic or paucisymptomatic despite carrying significant worm burdens.
1. Cercarial Dermatitis (Swimmer's Itch):
-
Occurs within minutes to hours of skin penetration by cercariae
-
Pruritic, erythematous, papular rash at the site of penetration
-
More prominent with non-human schistosome species (avian schistosomes common in temperate lakes)
-
Resolves spontaneously within 1-2 weeks
-
Often the first sign of infection in travelers
2. Acute Schistosomiasis (Katayama Syndrome):
-
Occurs 2-8 weeks after primary infection, coinciding with onset of egg production
-
Much more common in primary infections (travelers, non-immune individuals) than in residents of endemic areas
-
High fever (often >39°C), rigors, sweats
-
Nonproductive cough, wheeze (pulmonary infiltrates on chest X-ray)
-
Urticaria, angioedema
-
Hepatosplenomegaly with right upper quadrant pain
-
Marked eosinophilia (often >3000/uL)
-
Myalgia, arthralgia, headache, fatigue
-
Can be severe and occasionally fatal
-
Resolves over weeks but may persist for months if untreated
3. Chronic Intestinal Schistosomiasis (S. mansoni, S. japonicum):
-
Intermittent abdominal pain, particularly periumbilical or left lower quadrant
-
Bloody diarrhea (occult or visible blood)
-
Iron deficiency anemia
-
Fatigue, reduced exercise tolerance
-
Hepatomegaly (early) → hepatosplenomegaly (advanced)
-
Periportal (Symmers pipe-stem) fibrosis: Progressive fibrosis around portal vein branches, leading to portal hypertension
-
Ascites, esophageal varices with risk of variceal hemorrhage
-
S. japonicum typically causes more severe hepatic disease due to higher egg output
4. Chronic Urogenital Schistosomiasis (S. haematobium):
-
Hematuria — the hallmark symptom (often painless, terminal hematuria)
-
Dysuria, urinary frequency
-
Suprapubic discomfort
-
Hydronephrosis, hydroureter (ureteral stricture from egg granulomas)
-
Bladder fibrosis and calcification
-
Squamous cell carcinoma of the bladder (long-term complication)
-
Female genital schistosomiasis (FGS): Vulvar/vaginal lesions ("sandy patches"), pelvic pain, dyspareunia, irregular bleeding, infertility
-
Male genital schistosomiasis: Hematospermia, orchitis, prostatitis
Knowing the symptoms is the first step to a quick response.
Course of Disease
Disease Course and Progression
Schistosomiasis follows a complex natural history from initial skin penetration through chronic organ damage over years to decades.
Exposure and Skin Penetration (Minutes):
-
Cercariae released from infected freshwater snails penetrate intact human skin within minutes
-
Each cercaria sheds its tail and transforms into a schistosomulum (immature worm)
-
Penetration may cause cercarial dermatitis (pruritic papular rash) within hours
Migration Phase (Weeks 1-4):
-
Schistosomula enter dermal venules and lymphatics, reaching the lungs within days
-
Passage through pulmonary capillaries (may cause transient cough/wheeze)
-
Migration to the portal system via systemic circulation
-
Maturation in intrahepatic portal veins over 4-6 weeks
-
Male and female worms pair (they live as mated pairs for their entire lifespan)
Egg Production Phase (Week 5-8 onwards):
-
Paired adult worms migrate to their species-specific venous plexus:
- S. mansoni and S. japonicum → mesenteric venous plexus (intestinal)
- S. haematobium → vesical venous plexus (urogenital)
-
Female worms begin producing eggs (S. mansoni: ~300 eggs/day; S. japonicum: ~3,000 eggs/day; S. haematobium: ~200 eggs/day)
-
Some eggs penetrate vascular walls and pass through tissues to reach the intestinal or bladder lumen for excretion
-
Trapped eggs that fail to transit become lodged in tissues (liver, intestine, bladder, lungs, CNS), provoking granulomatous inflammation
Acute Phase — Katayama Syndrome (Weeks 2-8 post-exposure):
-
Hypersensitivity response to initial egg deposition and circulating immune complexes
-
More common and severe in primary infections (travelers, non-immune individuals)
-
Fever, eosinophilia, hepatosplenomegaly, urticaria, respiratory symptoms
-
Self-limiting over weeks to months
Chronic Phase (Months to Decades):
-
Progressive granulomatous inflammation and fibrosis around trapped eggs
-
Hepatosplenic disease: Periportal (Symmers) fibrosis → portal hypertension → esophageal varices → variceal hemorrhage
-
Urogenital disease: Bladder wall granulomas → fibrosis → calcification → obstructive uropathy → squamous cell carcinoma (decades)
-
Adult worms survive 3-10 years on average (reports of 30+ years)
-
Even after worm death, trapped eggs continue to provoke granulomatous responses
-
Without reinfection, egg excretion ceases within years as worms senesce
Resolution/Burnout: In some long-lived infections, a degree of immune modulation develops, with reduced granuloma size around older eggs. However, fibrosis persists and may progress even after worm death.
Diagnosis
How this disease is identified
Diagnosis
Schistosomiasis diagnosis uses parasitological, immunological, and molecular methods. The choice of test depends on the clinical setting (endemic area screening vs. individual traveler diagnosis) and the phase of infection.
Parasitological Methods (Direct Detection):
-
Stool Microscopy (S. mansoni, S. japonicum):
- Detection of characteristic eggs: S. mansoni (lateral spine), S. japonicum (small lateral knob)
- Kato-Katz thick smear — WHO-recommended quantitative method; enables intensity classification (light: 1-99 epg, moderate: 100-399 epg, heavy: >=400 eggs per gram)
- Sensitivity: 50-80% for single specimen; improves with multiple specimens (3 days recommended)
- Highly specific (100%)
-
Urine Microscopy (S. haematobium):
- Detection of terminal-spine eggs by urine filtration or sedimentation
- Collect urine between 10:00 AM and 2:00 PM (peak egg excretion)
- Sensitivity: 60-80% for single specimen
- Visual hematuria or positive urine dipstick for blood supports diagnosis
-
Tissue Biopsy:
- Rectal snip biopsy: high sensitivity for S. mansoni
- Bladder biopsy (cystoscopy): for S. haematobium, also for cancer surveillance
- Liver biopsy: demonstrates granulomas and fibrosis
Immunological Methods:
-
Point-of-Care Circulating Cathodic Antigen (POC-CCA) — Urine Test:
- Rapid lateral-flow immunoassay detecting S. mansoni adult worm antigen in urine
- Results in 20 minutes
- Sensitivity: 70-90% (comparable to or better than single Kato-Katz)
- Increasingly used in MDA programs for mapping
- Less reliable for S. haematobium
-
Serology (Antibody Detection):
- ELISA, IHA, or immunoblot detecting anti-schistosomal antibodies
- High sensitivity (>90%) — excellent for screening travelers
- Cannot distinguish active vs. past infection (antibodies persist for years)
- Most useful for travelers from non-endemic areas (any positive = significant)
- CDC uses immunoblot confirming species-specific bands
Molecular Methods:
- PCR:
- Detects schistosomal DNA in stool, urine, or serum
- Higher sensitivity than microscopy, especially for low-intensity infections
- Species identification possible
- Not yet widely available in endemic areas
Imaging:
-
Abdominal ultrasound: WHO-standardized protocol for assessing hepatosplenic disease (liver fibrosis pattern, portal vein diameter, spleen size). The Niamey protocol is used for grading periportal fibrosis.
-
CT/MRI: For neuroschistosomiasis diagnosis (spinal cord or cerebral granulomas)
-
Cystoscopy and IVP/CT urogram: For assessing bladder pathology and upper tract obstruction in S. haematobium
Treatment
Available treatment methods
Treatment and Management
The cornerstone of schistosomiasis treatment is praziquantel, which is effective against all human Schistosoma species. Treatment strategy depends on whether the infection is acute or chronic.
Praziquantel — First-Line Treatment:
-
S. mansoni and S. haematobium: 40 mg/kg in a single dose (or divided into two doses 4-6 hours apart)
-
S. japonicum and S. mekongi: 60 mg/kg divided into 2-3 doses over one day (higher egg burden)
-
Cure rate: 70-100% with a single treatment course
-
Egg reduction rate: >95% in most patients
-
Retreatment after 2-4 weeks may be needed if symptoms persist or eggs remain detectable
-
Side effects: generally mild and transient — nausea, abdominal pain, diarrhea, headache, dizziness. More common and intense with higher worm burdens.
-
Safe in pregnancy (WHO recommends treatment of pregnant women in endemic areas)
Important Note on Timing: Praziquantel is effective only against adult worms, not against immature schistosomula. In acute infections (Katayama syndrome), treatment should be given but may need to be repeated 6-8 weeks later to kill worms that were immature at the time of initial treatment.
Treatment of Acute Schistosomiasis (Katayama Syndrome):
-
Corticosteroids (prednisolone 1-2 mg/kg/day tapered over 2-3 weeks) — to control the hypersensitivity reaction
-
Praziquantel — given during the acute illness AND repeated at 6-8 weeks
-
Supportive care: antipyretics, hydration, bronchodilators if needed
Treatment of Neuroschistosomiasis:
-
Corticosteroids (high-dose dexamethasone or methylprednisolone) — URGENT to reduce inflammation and prevent permanent neurological damage
-
Praziquantel — given with steroid cover
-
Neurosurgical consultation for space-occupying lesions
Management of Advanced Hepatosplenic Disease:
-
Praziquantel kills adult worms and prevents further egg deposition but does not reverse established fibrosis
-
Portal hypertension management: non-selective beta-blockers, endoscopic variceal banding
-
Variceal hemorrhage: emergency endoscopy, blood transfusion, vasoactive agents (octreotide)
-
Surgical portosystemic shunts or TIPS for recurrent variceal bleeding
Management of Urogenital Complications:
-
Praziquantel for active infection
-
Ureteral stenting or surgical repair for obstructive uropathy
-
Bladder cancer surveillance (cystoscopy) for patients with longstanding S. haematobium infection
-
FGS: praziquantel with gynecological follow-up
Mass Drug Administration (MDA): WHO recommends preventive chemotherapy with praziquantel for all school-age children and at-risk adults in endemic areas, delivered through MDA programs annually or biannually.
Most cases are effectively treated with early diagnosis.
Prevention Details
How to protect yourself
Prevention Strategies
There is currently no licensed vaccine for schistosomiasis. Prevention relies on avoiding contaminated freshwater, mass drug administration, snail control, and improved water and sanitation.
Personal Protective Measures (Travelers):
-
Avoid all freshwater contact in endemic areas: do not swim, wade, bathe, or wash in rivers, lakes, streams, irrigation canals, or dams where schistosomiasis is transmitted
-
If accidental freshwater exposure occurs, vigorously towel-dry the skin immediately (cercarial penetration takes several minutes)
-
Water safety: Use only treated, filtered, or heated water for bathing. Water heated to >50°C (122°F) for 5 minutes or held in a tank for >48 hours is safe.
-
Topical repellents: DEET and niclosamide-based creams have shown some protective effect in studies but are not reliably protective
-
Note: Saltwater and adequately chlorinated swimming pools are safe
-
Cercariae cannot penetrate intact rubber/waterproof boots, but exposed skin is vulnerable
Mass Drug Administration (MDA):
-
WHO recommends preventive chemotherapy with praziquantel for:
- All school-age children (5-14 years) in endemic areas
- At-risk adults (fishermen, farmers, irrigation workers, women performing domestic chores in contaminated water)
-
Frequency: annually in high-transmission areas (>=50% prevalence); biennially in moderate areas (10-50%)
-
MDA has been the single most impactful intervention for reducing schistosomiasis morbidity globally
-
Limitations: MDA does not prevent reinfection and must be sustained
Snail Control:
-
Molluscicides (niclosamide): Chemical control of snail intermediate hosts in transmission sites
-
Biological control: Introduction of snail predators or competitor species
-
Environmental management: Drainage of swampy areas, modification of irrigation channels
-
Integrated vector management combining multiple approaches is most effective
Water, Sanitation, and Hygiene (WASH):
-
Provision of safe water supplies reduces the need for freshwater contact
-
Improved sanitation (latrines, sewage treatment) prevents egg contamination of water bodies
-
Health education on avoidance of freshwater contact
Vaccine Development:
-
Sm14 (S. mansoni fatty acid binding protein): Phase 2/3 trials underway in Brazil and Senegal
-
Sh28GST (Bilhvax): Phase 3 trial completed for S. haematobium
-
SchistoShield (Sm-p80): Preclinical and Phase 1
-
A practical vaccine remains several years from licensure
Preparation is the best protection.
Travel Advice
Travel Advice
Schistosomiasis is one of the most common parasitic infections acquired by travelers. Even brief freshwater exposure in endemic areas can result in infection.
High-Risk Destinations:
-
Sub-Saharan Africa: The highest risk region globally. Lake Malawi, Lake Victoria, Lake Tanganyika, the Nile basin (Uganda, Egypt, Sudan), and rivers throughout West, Central, and East Africa are well-documented transmission sites.
-
Southeast Asia: Philippines (S. japonicum), parts of Laos and Cambodia (S. mekongi)
-
South America: Brazil (especially northeastern states — Bahia, Minas Gerais, Pernambuco), Suriname, Venezuela
-
Middle East: Yemen, parts of Iraq
-
Caribbean: Historically in some islands; risk now minimal in most
Common Exposure Scenarios for Travelers:
-
Swimming or bathing in Lake Malawi (a very common traveler exposure)
-
Rafting or kayaking on rivers in East/West Africa
-
Wading across streams during trekking (East Africa, Madagascar)
-
Bathing in waterfalls in West Africa or Brazil
-
Participating in freshwater activities during voluntourism or gap year travel
Pre-Travel Recommendations:
- Consult a travel health provider before departure
- Be informed about schistosomiasis risk at your specific destination
- Plan: If freshwater activities are desired, identify safe alternatives (ocean, chlorinated pools)
- Know that brief exposure (even a few minutes of wading) can be sufficient for infection
- No chemoprophylaxis or vaccine is available
During Travel:
-
Avoid ALL freshwater contact in endemic areas — swimming, wading, washing, even brief water crossings
-
If accidental exposure occurs, immediately towel-dry thoroughly
-
Use treated water (boiled or held >48 hours) for bathing
-
Ocean swimming and properly maintained swimming pools are safe
Post-Travel:
-
All travelers with freshwater exposure in endemic areas should be screened for schistosomiasis, even if asymptomatic
-
Screening should occur at least 8-12 weeks after last exposure (to allow antibody development and egg production)
-
Testing: serology (antibody detection) is the most sensitive test for travelers; stool/urine microscopy has low sensitivity for light infections
-
Eosinophilia on routine blood work should prompt evaluation for schistosomiasis in returned travelers
-
Treatment with praziquantel is simple, safe, and curative
-
Early treatment prevents all long-term complications
How common is it?
Statistics and geographic data
Epidemiology
Schistosomiasis is one of the most prevalent parasitic diseases globally, with a distribution determined by the presence of suitable freshwater snail hosts and human freshwater contact patterns.
Global Burden:
-
240 million people infected in 78 countries (WHO estimate)
-
700 million at risk in endemic areas
-
~11,700-200,000 deaths annually (GBD 2019: ~11,700; older WHO estimates: ~200,000; primarily from hepatosplenic and urogenital complications)
-
4.5 million DALYs lost annually (likely underestimated)
-
Over 90% of the global burden is in sub-Saharan Africa
-
Second only to malaria among parasitic diseases in terms of socioeconomic impact
Species Distribution:
-
S. mansoni: Africa (widespread), Middle East (Yemen, Saudi Arabia), South America (Brazil, Venezuela, Suriname), Caribbean (historically)
-
S. haematobium: Africa (widespread), Middle East (Iraq, Yemen), Corsica (France — newly emerged focus since 2013)
-
S. japonicum: China (Yangtze River basin — greatly reduced), Philippines (Leyte, Mindanao, others), Indonesia (Sulawesi)
-
S. mekongi: Laos, Cambodia (Mekong River)
-
S. intercalatum/guineensis: West and Central Africa (limited foci)
Prevalence Patterns:
-
Prevalence peaks in children aged 10-14 years (can exceed 80% in high-transmission areas)
-
Infection intensity (egg counts) also peaks in this age group
-
Adults develop partial immunity, resulting in lower intensity with age
-
Urban transmission is increasingly recognized (e.g., Kinshasa, Dar es Salaam)
Notable Epidemiological Developments:
-
Corsica, France: Autochthonous S. haematobium transmission since 2013 — first known European focus in modern times, linked to hybridization with livestock schistosomes
-
China: Dramatic reduction in S. japonicum through integrated control (from 12 million infected in 1950s to <30,000 currently), but elimination remains elusive
-
Dam and irrigation projects: Consistently associated with new or increased schistosomiasis transmission (e.g., Aswan Dam/Egypt, Three Gorges/China)
WHO Control Strategy:
-
Preventive chemotherapy via MDA with praziquantel
-
Target: treat >=75% of school-age children in endemic areas
-
By 2023, >100 million people treated annually through MDA programs
-
Goal: elimination as a public health problem by 2030 (defined as <1% heavy-intensity infections in all endemic areas)
Climate Change:
-
Potential expansion of snail habitats into currently non-endemic areas (southern Europe, higher altitudes in Africa)
-
Changes in rainfall and water management patterns may alter transmission dynamics
Risk Factors
Who is most at risk
Risk Factors
Risk factors for schistosomiasis infection and severe disease relate to freshwater exposure patterns, geographic location, and host factors.
Risk Factors for Infection:
-
Freshwater contact in endemic areas: The essential risk factor. Any skin exposure to cercariae-contaminated freshwater can result in infection.
-
Geographic location: Living in or traveling to endemic areas with active transmission
-
Age and water contact patterns: School-age children (5-14 years) have the highest prevalence and intensity in endemic areas due to frequent recreational and domestic water contact
-
Occupational exposure:
- Fishermen and fish farmers
- Rice paddy farmers
- Irrigation workers
- Laundry workers using freshwater sources
- Sand miners
- Ferry operators and boatmen
-
Domestic water use: Washing clothes, bathing, fetching water from contaminated sources
-
Recreational exposure: Swimming, playing, bathing in contaminated freshwater
-
Absence of safe water supply: Communities without piped water are dependent on contaminated surface water
-
Seasonal factors: Transmission may be seasonal in some areas (linked to snail population dynamics and rainfall)
Risk Factors for Severe/Chronic Disease:
-
Intensity of infection: High worm burden (reflected by high egg counts) is the strongest determinant of organ damage
-
Duration of infection: Years to decades of untreated infection increase cumulative tissue damage
-
Reinfection: Repeated reinfection maintains high worm burdens and egg deposition
-
Species: S. japonicum produces ~10x more eggs than S. mansoni, causing more rapid hepatic fibrosis
-
Co-infection with hepatitis B or C: Dramatically worsens hepatic schistosomiasis; co-infection accelerates fibrosis and increases mortality from liver disease
-
Genetic factors: HLA type and immunogenetic variation influence granuloma formation and fibrosis
-
Nutritional status: Malnutrition increases susceptibility to disease manifestations
-
HIV co-infection: May alter immune response to schistosome eggs; reduces efficacy of praziquantel
Protective Factors:
-
Partial immunity develops with age and repeated exposure (adults in endemic areas typically have lower infection intensity than children)
-
Praziquantel treatment reduces worm burden and morbidity
-
Safe water supply and improved sanitation eliminate exposure
-
Health education on avoidance of freshwater contact
Complications Details
Potential complications
Complications
Schistosomiasis complications are driven by the granulomatous immune response to trapped eggs in tissues, leading to progressive fibrosis and organ damage over months to decades.
Hepatosplenic Complications (S. mansoni, S. japonicum):
-
Periportal (Symmers pipe-stem) fibrosis: The pathognomonic lesion of hepatosplenic schistosomiasis. Granulomatous inflammation around portal tracts leads to characteristic periportal fibrosis visualized on ultrasound. Unlike cirrhosis, hepatocellular function is generally preserved.
-
Portal hypertension: Progressive periportal fibrosis obstructs portal blood flow, leading to elevated portal pressure, splenomegaly, and portosystemic collateral formation.
-
Esophageal and gastric varices: The most dangerous complication of portal hypertension. Variceal hemorrhage is a leading cause of death in hepatosplenic schistosomiasis, with mortality of 20-30% per bleeding episode.
-
Massive splenomegaly: With hypersplenism (pancytopenia) — common in advanced disease.
-
Ascites: Develops in advanced portal hypertension.
-
Hepatic decompensation: Uncommon with pure schistosomal fibrosis but occurs when co-infected with hepatitis B or C (synergistic liver damage).
Urogenital Complications (S. haematobium):
-
Bladder fibrosis and calcification: Progressive thickening and calcification of the bladder wall, visible on imaging. Reduces bladder capacity.
-
Hydronephrosis and hydroureter: Ureteral egg granulomas cause strictures and obstruction, leading to progressive upper tract dilation and chronic renal failure.
-
Squamous cell carcinoma of the bladder: S. haematobium is an IARC Group 1 carcinogen. Bladder cancer incidence in high-transmission areas is dramatically elevated. Typically presents at younger ages (40s-50s) compared to non-schistosomal bladder cancer.
-
Female genital schistosomiasis (FGS): Affects an estimated 56 million women and girls. Cervical and vaginal granulomas ("sandy patches") cause contact bleeding, discharge, dyspareunia, chronic pelvic pain, and infertility. FGS increases HIV acquisition risk by 3-4 fold due to disruption of the genital mucosal barrier.
-
Male genital involvement: Hematospermia, prostatitis, orchitis, epididymitis. May contribute to infertility.
Neurological Complications (All Species):
-
Spinal cord schistosomiasis: Most common with S. mansoni. Egg deposition in the spinal cord (usually lower thoracic/conus medullaris) causes granulomatous transverse myelitis. Presents with acute or subacute lower limb weakness, sensory level, and sphincter dysfunction. Requires urgent treatment with corticosteroids and praziquantel.
-
Cerebral schistosomiasis: More common with S. japonicum (due to smaller egg size crossing the pulmonary filter). Presents with seizures, raised intracranial pressure, focal deficits.
Pulmonary Complications:
-
Pulmonary hypertension (cor pulmonale): Eggs embolize to pulmonary arterioles, causing granulomatous arteritis and progressive pulmonary hypertension. More common with hepatosplenic disease (portosystemic shunting allows eggs to bypass the liver).
-
Respiratory symptoms: Cough, dyspnea in advanced pulmonary involvement.
Renal Complications:
-
Glomerulonephritis: Immune complex deposition in glomeruli (particularly with S. mansoni), leading to nephrotic syndrome.
-
Chronic kidney disease: From obstructive uropathy (S. haematobium) or glomerulonephritis.
Nutritional and Developmental Impact:
- Chronic schistosomiasis in children causes iron deficiency anemia, protein-calorie malnutrition, growth stunting, and impaired cognitive development — substantial impacts on educational attainment and future economic productivity.
Recovery & Outlook
Expected outcomes and recovery
Prognosis and Outcomes
The prognosis for schistosomiasis depends critically on the intensity and duration of infection, the species involved, and access to treatment.
Acute Schistosomiasis (Katayama Syndrome):
-
Generally good prognosis with appropriate treatment (corticosteroids + praziquantel)
-
Self-limiting even without treatment in most cases, though recovery may take months
-
Rarely fatal, but severe cases (particularly with neurological or respiratory involvement) can be life-threatening
-
Travelers may experience prolonged eosinophilia and fatigue even after treatment
Chronic Schistosomiasis — With Treatment:
-
Early treatment (before significant fibrosis): Excellent prognosis. Praziquantel eliminates adult worms, stops new egg deposition, and allows resolution of inflammation. Mild hepatic and urinary changes are largely reversible.
-
Cure rates: 70-100% with single-dose praziquantel
-
Egg reduction rates: >95%
-
Reinfection: Common in endemic areas without sustained MDA programs. Repeated treatment reduces cumulative morbidity.
Chronic Schistosomiasis — Without Treatment:
-
Progressive organ damage over years to decades
-
Hepatosplenic disease (S. mansoni/japonicum): Portal hypertension, esophageal varices (risk of fatal hemorrhage), hepatosplenomegaly. Note: hepatocellular function is typically preserved (unlike cirrhosis) unless concurrent viral hepatitis is present.
-
Urogenital disease (S. haematobium): Progressive bladder fibrosis, hydronephrosis, chronic renal failure. Squamous cell carcinoma of the bladder — S. haematobium is a IARC Group 1 carcinogen; bladder cancer incidence is markedly elevated in high-transmission areas.
Neurological Prognosis:
-
Spinal cord disease: If treated promptly with corticosteroids and praziquantel, significant neurological recovery is possible. Delayed treatment results in permanent paraplegia.
-
Cerebral disease: Variable outcomes; seizure disorders may persist
Impact on Child Development: In endemic areas, chronic schistosomiasis in children is associated with:
-
Iron deficiency anemia and malnutrition
-
Stunted growth and physical development
-
Impaired cognitive development and reduced school performance
-
These effects are substantially reversible with treatment and nutritional support
Life Expectancy:
-
Untreated hepatosplenic schistosomiasis with portal hypertension reduces life expectancy significantly
-
Treated patients, even with established fibrosis, can have near-normal life expectancy with appropriate portal hypertension management
-
S. haematobium-related bladder cancer is the major cause of schistosomiasis-attributable mortality
